Equity Overview
Price & Market Data
Price: $0.382
Daily Change: -$0.0081 / 2.12%
Daily Range: $0.382 - $0.402
Market Cap: $2,715,265
Daily Volume: 71,089
Performance Metrics
1 Week: -10.80%
1 Month: -32.49%
3 Months: -29.22%
6 Months: -45.83%
1 Year: -58.73%
YTD: -30.60%
Details
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.